Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis

被引：21

作者：

Al-Badri, Marwa R. ^{[1
]}

Azar, Sami T. ^{[1
]}

机构：

[1] Amer Univ Beirut Med Ctr, Div Endocrinol & Metab, Dept Internal Med, 3 Dag Hammarskjold Plaza,8th Floor, New York, NY 10017 USA

来源：

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM | 2014年 / 5卷 / 02期

关键词：

dipeptidyl peptidase-4 inhibitors; glucagon-like peptide-1; glycemic control; incretin; liraglutide; metabolic syndrome; obesity; psoriasis; type; 2; diabetes;

D O I：

10.1177/2042018814543483

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis.

引用

页码：34 / 38

页数：5

共 11 条

[1] Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study [J].

Ahern, T. ;

Tobin, A. -M. ;

Corrigan, M. ;

Hogan, A. ;

Sweeney, C. ;

Kirby, B. ;

O'Shea, D. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (11) :1440-1443

[2] Improvement of psoriasis during exenatide treatment in a patient with diabetes [J].

Buysschaert, M. ;

Tennstedt, D. ;

Preumont, V. .

DIABETES & METABOLISM, 2012, 38 (01) :86-88

[3] Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology [J].

Drucker, D. J. ;

Rosen, C. F. .

DIABETOLOGIA, 2011, 54 (11) :2741-2744

[4] Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide [J].

Faurschou, A. ;

Knop, F. K. ;

Thyssen, J. P. ;

Zachariae, C. ;

Skov, L. ;

Vilsboll, T. .

ACTA DIABETOLOGICA, 2014, 51 (01) :147-150

[5] Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques [J].

Faurschou, Annesofie ;

Pedersen, Jens ;

Gyldenlove, Mette ;

Poulsen, Steen S. ;

Holst, Jens J. ;

Thyssen, Jacob P. ;

Zachariae, Claus ;

Vilsboll, Tina ;

Skov, Lone ;

Knop, Filip K. .

EXPERIMENTAL DERMATOLOGY, 2013, 22 (02) :150-152

[6] Gastric bypass surgery: Improving psoriasis through a GLP-1-dependent mechanism? [J].

Faurschou, Annesofie ;

Zachariae, Claus ;

Skov, Lone ;

Vilsboll, Tina ;

Knop, Filip K. .

MEDICAL HYPOTHESES, 2011, 77 (06) :1098-1101

[7] Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis [J].

Hogan, A. E. ;

Tobin, A. M. ;

Ahern, T. ;

Corrigan, M. A. ;

Gaoatswe, G. ;

Jackson, R. ;

O'Reilly, V. ;

Lynch, L. ;

Doherty, D. G. ;

Moynagh, P. N. ;

Kirby, B. ;

O'Connell, J. ;

O'Shea, D. .

DIABETOLOGIA, 2011, 54 (11) :2745-2754

[8] Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis [J].

Nishioka, Tatsuya ;

Shinohara, Masayuki ;

Tanimoto, Noriyasu ;

Kumagai, Chizuru ;

Hashimoto, Kozo .

DERMATOLOGY, 2012, 224 (01) :20-21

[9] Diagnosis and classification of psoriasis [J].

Raychaudhuri, Smriti K. ;

Maverakis, Emanual ;

Raychaudhuri, Siba P. .

AUTOIMMUNITY REVIEWS, 2014, 13 (4-5) :490-495

[10] Liraglutide in combination with acitretin for severe recalcitrant psoriasis [J].

Reid, C. T. ;

Tobin, A. M. ;

Ahern, T. ;

O'Shea, D. ;

Kirby, B. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (01) :230-231

← 1 2 →